Besides, we evaluated the therapeutic effects of combined cilengitide and anti-PD1 antibody in a murine melanoma model, including characterizing CD4+ and CD8+ tumor infiltrating lymphocytes (TILs) in both subcutaneous tumors and spleens of mice. Here, CD8A is linked to melanoma.